Esperion Therapeutics Inc...

NASDAQ: ESPR · Real-Time Price · USD
2.15
0.08 (3.86%)
At close: Aug 15, 2025, 9:56 AM

Esperion Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
82.39M 65M 69.11M 51.63M 73.83M 137.74M 32.25M 33.97M 25.79M 24.33M 18.82M 18.98M 18.84M 18.84M 15.4M 14.41M 40.66M 7.98M
Cost of Revenue
20.61M 31.54M 25.63M 17.29M 15.61M 10.07M 11.45M 13.38M 6.79M 11.65M 4.16M 6.51M 9.18M 7.13M 5.08M 5.56M 1.8M 1.78M
Gross Profit
61.78M 33.46M 43.48M 34.35M 58.23M 127.66M 20.8M 20.59M 19M 12.68M 14.66M 12.47M 9.66M 11.71M 10.33M 8.85M 38.86M 6.19M
Operating Income
15.03M -22.1M -4.42M -16.03M 2.58M 72.27M -42.37M -27.53M -37.06M -48.6M -42.51M -41.62M -52.38M -42.99M -55.63M -55.74M -32.53M -82.82M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-4.79M -40.45M -21.32M -29.52M -61.92M 61.02M -56.34M -41.25M -49.94M -61.72M -55.49M -55.12M -66.32M -56.73M -65.12M -69.39M -43.67M -90.94M
Net Income
-4.79M -40.45M -21.32M -29.52M -61.92M 61.02M -56.34M -41.25M -49.94M -89.22M -68.46M -68.61M -80.27M -70.47M -65.12M -69.39M -43.67M -90.94M
Selling & General & Admin
39.51M 43M 36.92M 39.98M 44.19M 41.99M 45.42M 33.24M 33.96M 29.9M 24.14M 24.95M 29.61M 30.38M 38.34M 39.27M 46.32M 61.06M
Research & Development
7.24M 12.56M 10.98M 10.4M 11.46M 13.4M 17.74M 14.88M 22.1M 31.38M 33.03M 29.14M 32.43M 24.32M 27.62M 25.33M 25.07M 27.95M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 318K 320K n/a 13K 9K 14K
Operating Expenses
46.75M 55.55M 47.9M 50.37M 55.65M 55.39M 63.16M 48.13M 56.06M 61.28M 57.17M 54.1M 62.04M 54.7M 65.95M 64.6M 71.39M 89.02M
Interest Expense
20.49M 19.43M 16.42M 15.08M 13.72M 14.02M 15.06M 14.99M 14.54M 14.39M 14.33M 14.15M 14.27M 14.06M 13.43M 13.65M 11.14M 8.13M
Selling & Marketing Expenses
n/a n/a 25.5M n/a n/a n/a n/a n/a n/a n/a 11.3M n/a n/a n/a 13.7M n/a n/a n/a
Cost & Expenses
67.36M 87.09M 73.53M 67.66M 71.25M 65.47M 74.62M 61.5M 62.84M 72.93M 61.33M 60.6M 71.22M 61.83M 71.03M 70.15M 73.19M 90.8M
Income Tax Expense
n/a n/a n/a n/a n/a -41K n/a -26K -51K 27.5M 12.97M 13.49M 13.95M 13.74M n/a n/a n/a n/a
Shares Outstanding (Basic)
196.84M 196.13M 195.57M 194.93M 188.79M 169.26M 112.4M 111.87M 109.24M 78.44M 73.49M 67.81M 63.23M 60.95M 36.85M 26.46M 26.23M 25.99M
Shares Outstanding (Diluted)
196.84M 196.13M 195.57M 194.93M 188.79M 189.64M 112.4M 111.87M 109.24M 78.44M 73.49M 67.81M 63.23M 60.95M 36.85M 26.46M 26.23M 25.99M
EPS (Basic)
-0.02 -0.21 -0.11 -0.15 -0.33 0.36 -0.5 -0.37 -0.46 -1.14 -0.93 -1.01 -1.27 -1.16 -1.77 -2.62 -1.67 -3.5
EPS (Diluted)
-0.02 -0.21 -0.11 -0.15 -0.33 0.34 -0.5 -0.37 -0.46 -1.14 -0.93 -1.01 -1.27 -1.16 -1.77 -2.62 -1.67 -3.5
EBITDA
15.7M -21M -4.87M -14.42M -48.19M 75.05M -41.28M -26.23M -35.35M -47.25M -41.07M -40.86M -51.91M -42.52M -51.54M -55.58M -32.37M -82.66M
EBIT
15.7M -21.02M -4.9M -14.44M -48.2M 75.05M -41.29M -26.25M -35.4M -47.33M -41.16M -40.96M -52.06M -42.67M -51.69M -55.73M -32.52M -82.81M
Depreciation & Amortization
-26K 26K 27K 26K 10K 41K 6K 26K 51K 81K 92K 105K 150K 153K 153K 153K 153K 153K